Kiniksa Pharmaceuticals International, plc
KNSA
Rank in Stocks
#2961
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Share Price
$79.61
Last synced: 2026-10-19
Market Cap
$6.21B
Change (1 day)
1.30%
Change (1 year)
104.18%
Country
GB
Trade Kiniksa Pharmaceuticals International, plc (KNSA)
Category
Healthcare
Stock split history for Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc stock (symbol: KNSA) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One KNSA share bought prior to Oct 20, 2026 would equal to 0 KNSA shares today.
The most recent stock split occurred on Oct 20, 2026.
One KNSA share bought prior to Oct 20, 2026 would equal to 0 KNSA shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 7 | x40 |
HK
|
